Applications
The power of digital analysis at your fingertips
Liver
Liver
• MASH/MAFLD
Lung
Lung
• Pulmonary Hypertension
• Emphysema
Kidney
Kidney
Heart
Heart
Skin
Skin
Others
Others
• IHC quantification for MoA investigation
Pulmonary Fibrosis
Pulmonary fibrosis is an active therapeutic area in drug development. The lung scarring and thickening that occurs in pulmonary fibrosis cannot be repaired. And no current treatment has proved effective in stopping the disease from getting worse over time.
Histology is part of preclinical drug assessment and as well as clinical diagnosis in patients.
A unique multiparametric image analysis have been developed to measure key morphometric endpoints of pulmonary fibrosis with high accuracy and reliability.
Emphysema
Emphysema is a lung condition that causes shortness of breath. In people with emphysema, the air sacs in the lungs (alveoli) are damaged. Over time, the inner walls of the air sacs weaken and rupture — creating larger air spaces instead of many small ones. This reduces the surface area of the lungs and, in turn, the amount of oxygen that reaches your bloodstream.
Histology is part of preclinical drug assessment.
A unique multiparametric image analysis have been developed to measure key morphometric endpoints of emphysema with high accuracy and reliability.
Pulmonary Hypertension
A digital pathology technology able to see beyond the human eye capability
Visual histological assessment of pulmonary hypertension (PH) is particularly tedious. Beside its non-exhaustive character, the current methodology is extremely time-consuming and suffers from high variability.
To tackle these challenges, Biocellvia has developed a unique multiparametric image analysis. MorphoQuant assesses the key morphometric features of PH with high accuracy and reliability:
- Blood vessel detection and classification per size
- Measurements of muscular and endothelial layers for each detected blood vessel
- Detection of obstructed vessels and plexiform lesions
- Exploratory endpoints
MASLD / MASH / Liver Fibrosis
Several chronic liver diseases, including MASLD (formerly NAFLD) and its severe form MASH (formerly known as NASH) can lead to severe liver fibrosis, including cirrhosis. MASH severity assessment has been repeatedly shown to be subjective.
A unique multiparametric image analysis have been developed bring objectivity, accuracy and confidence to the pathologists for the assessment of steatosis-, inflammation-, ballooning- and fibrosis-related outputs, and allow more granularity by providing quantitative data versus a score.
Kidney Fibrosis
Renal fibrosis is one pathology out of many in the metabolic syndrome. It is defined as the progressive development of fibrosis in the kidney and may lead to acute kidney failure.
A unique multiparametric image analysis have been developed to measure key morphometric endpoints of kidney fibrosis with high accuracy and reliability.
IHCs & Exploratory
MorphoQuant™ can also assess all types of immuno-histochemistry! Discover our list:
- arginase-1
- a-smooth muscle actin (a-SMA)
- CD45
- CD68
- CK19
- COL1A1
- F4/80
- Galectin-3
- hFAP
- IRF5
- Ly6G
- MUC5AC
- p16
- p21
- Shh
- Vimentin
- Von Willebrand Factor (VWF)
By using a morphometric and deterministic approach, additional features can be easily added to MorphoQuant, even with a limited number of images. Our approach, which combines the use of dedicated histology and our « non-training » approach enables the detection and quantification of new outputs of interest with high-success rate.
Entrust us with your new project and a new robust « clé-en-main » solution will be developed to answer your needs. Full automation will ensure great consistency across all your studies and an unprecedent control over your study data.